Basi
BASI is a national pharmaceutical group located in Coimbra, the biggest
health industry centre in Portugal.
The facilities, quality and know-how of the employees, and the
dynamism and experience of the management team mean we operate in
accordance with the highest standards of quality.
BASI offers a wide diversity of products, from non-steroidal antiinflammatories (NSAIDs) to Central Nervous System (CNS) products,
and is also present in dynamic market segments such as the
cardiovascular area and infectious diseases. BASI produces and
markets its own wide range of products in addition to marketing licensed
products. BASI can facilitate the launch of clinical trials of medicines
in Portugal due to its close and firm relationship with Opinion Leaders
and important clinical centres at the University Hospital of Coimbra.
BASI wants to strengthen its position in the national market and to
continue developing its sustainable international programme.

Bial
To develop, achieve and provide new therapeutic health solutions.
Bial focuses on the research, production and marketing of pharmaceutical
specialties.

Bluepharma
Bluepharma is a pharmaceutical company, of national capital, based in
Coimbra, Portugal. Basing itself on the excellence of the manufacturing
unit acquired from Bayer, one of the most advanced and well designed
in the country, and on the quality and training of its partners and the
experience and dynamism of its management team, Bluepharma is
one of the most dynamic and modern companies competing on the
Portuguese pharmaceutical market. Bluepharma was the first
pharmaceutical company in Portugal to operate with integrated
certification in accordance with ISO standards 9001 and 14001 and
OHSAS 18 001, and the first in the pharmaceutical industry to be
granted the EMAS environmental certificate, the most demanding
European environmental certification. The company has established
various partnerships for research and development projects that are
currently under way. With partners AIBILI and CNC, the company
entered a project for PRAI, and won the European Prize for Regional
Innovation for Portugal (2004) and recognition of project X-Prot. In
the industrial arena, and despite Bayer transferring all its production
to other countries, the company has managed to find enough clients and
projects to make use of the factory’s capacity, estimated at 10 million units per year per shift. One of the biggest investment is taking place with the aim of doubling the prodution capacity. In Portugal, the company has developed its marketing of generic medicines reaching 30 medicines on the market by December 2007. It has an office in Lisbon with 30 employees.

Edol
Laboratório Edol, web site www.edol.pt is a pharmaceutical company
of exclusively Portuguese capital. It celebrated 54 years of age in 2006.
It has 86 employees, working in Administration & Finance,
Manufacturing, Quality Control, Regulatory Affairs, Medical,
Marketing and Sales, Research and Development and New Business
departments.
Laboratório Edol specialises in the development, production and
marketing of products in the following areas: Ophthalmology;
Dermatology, Dermocosmetics, Medical Devices. It also uses the excess
capacity of its production lines for contract manufacturing.
From 2001 to 2004, Laboratório Edol successively obtained, renewed
and integrated the following certificates; ISO 9001:2000 - Quality
(transition from ISO 9001:1995); ISO 14001 – Environment; OHSAS
18001 – Occupation Health and Safety and ISO 13 485 -Medical Devices.
Edol-Themaxis is a partnership with the Brazilian multinational,
Europharma. It is exclusively dedicated to the marketing of generic
medicines. It has a sales force of nine employees.

Grupo tecnimede
Tecnimede Group develops, registers, manufactures, promotes and
sells pharmaceutical products for human use.
The Group has three commercial companies (Tecnimede, Pentafarma
and Farmoz), one production unit (West Pharma), R&D facilities (Labor
Qualitas) and two foreign subsidiaries with commercial activities
(Tecnimede Morocco and Tecnimede Spain).
The production unit, West Pharma, is located in Lisbon. It specialises in
the manufacture of oral solid products and is accredited by IPAC and
certified in accordance with Good Manufacturing Practices (GMP) and
ISO 9001:2000.
Labor Qaulitas is located 40 km north of Lisbon. It is an R&D facility,
accredited by IPAC and certified in accordance with Good Laboratory
Practices (GLP) and ISO 17025:2005 and chapter 6 of GMP, which
allows it to conduct the batch release and certification of all types of
pharmaceuticals.
Through Labor Qualitas, the Group conducts research and development
of new chemicals, new forms of synthesis and pharmaceutical formulation,
analytical development and validation of processes, pharmacological
screening, toxicology studies, clinical studies.
Tecnimede Group has vast experience in conducting BD/BE studies,
working with CROs in Portugal, Spain, France and Canada, and has
developed a portfolio of more then 40 generic products at Labor
Qualitas. These are being registered in almost all countries of the
European Union.

Iberfar
IBERFAR is part of a Portuguese pharmaceutical group that operates in
all fields of the industry. It manufactures solid and liquid forms for third
parties. Its distinctive skills are quality, turn-around time for orders and
adaptability to the needs of clients.

Jaba Recordati
Jaba Recordati A.A. has formed part of the Recordati Group since 2006.
Founded in 1927, in a small Lisbon pharmacy, it became one of the
most important companies in the Portuguese health market during
the following four decades.
Our activities are strategically focused to respond to the needs of our
clients and are therefore structured into five major business areas:
Contract Manufacturing, Generics, Pharma, Consumer Health and
Hospitals and Exports.
The name Jaba Recordati stands not only for quality products but also
for reliable service and innovation.
Our industrial units for contract manufacturing are in modern factories
that meet the most exacting European quality standards. This powerful
resource allows us to respond to the demand for the production of
generic or brand products and still react quickly to changes in the
needs of our clients.
Like all the Group’s other business activities, Jaba Recordati’s contract
manufacturing operations are characterised by great concern for
quality standards and an attention to detail that our clients greatly
value.

Labesfal
Starting as a family owned company, Labesfal grew to become one
of the biggest and most successful companies in Portugal with a vast
portfolio and a state-of-the-art manufacturing site, with technologies
that are unique in Portugal. It is market leader in the hospital market
and is in the top five in the generics market.
As a contract manufacturer, Labesfal produces for 30 national and
international companies in over 60 countries.
Labesfal is a 100% owned subsidiary of Fresenius Kabi and is the
location for the Fresenius Kabi Skills Centre for the development and
production of Pharmaceutical IV Medicinal Products.
Fresenius Kabi is the leader in Infusion Therapy and Clinical Nutrition in
Europe and in the most important countries of Latin America and the
Asia Pacific region. In addition, we are active in the field of Transfusion
Technology, supplying blood processing systems as well as blood bags
and filters. We focus on the therapy and care of critically and chronically
ill patients in and outside hospital.
Fresenius Kabi has more than 15,000 employees worldwide and a
global network of 50 sales organizations and 46 production sites. We
achieved sales of € 1.9 thousand million in 2006. Fresenius Kabi AG is a
100% owned subsidiary of the health care group Fresenius SE
(www.fresenius-ag.com).

Laboratórios Azevedos
The history of AZEVEDOS covers more than two centuries. At present,
the structure has five areas of intervention (R&D, production, marketing
and sales, logistics and international). In the industrial area, SOFARIMEX
(Azevedos Group) is the leading Portuguese producer of medicines.
It specialises in small and medium batches, and exports more than
50% of its production. AZEVEDOS markets a wide range of products
ensuring a significant availability of prescription and non-prescription
products and hospital specialities. DLA Farmacêutica (Azevedos Group)
is responsible for the logistical operations of the Group’s companies as
well as of those of a significant number of clients. Since the beginning
of the 1990s, AZEVEDOS has pursued internationalisation as a strategic
target for its development. It exports to, licenses products or has direct
investments in more than 43 international markets. In terms of specific
direct investment, MEDIS is a key player in the Mozambique market.
LABORIS BRAZIL is the group’s second most important manufacturing
unit and serves the vast MERCOSUL market. A decisive step for the
evolution of AZEVEDOS was its commitment to R&D. As a result of
continuous research and a constant search for information with which
to exploit new opportunities, this area of intervention has opened up
new perspectives, the only way of enabling a constant improvement in
products and services bearing the AZEVEDOS brand. R&D has ensured
that AZEVEDOS is a leader in the sector and has focused activity on the
development of new pharmaceutical formulas, analytical methods and
productive processes.

Laboratórios Vitória
Laboratórios Vitória was founded in 1943, to manufacture pharmaceutical
companies for the Portuguese market. Amongst the founding
shareholders were some very well known Portuguese business
personalities and politicians and the Spanish Chemical-Pharmaceutical
Enterprise FAES, the company’s current owner.
The headquarters, warehouses and production facilities are
located near Lisbon (Venda Nova -Amadora) and cover an area
of 8,000 m2. They form a modern and functional unit that uses the
latest technologies and that has been completely refurbished during
recent years, in accordance with international standards, GMPs and ISO
9002 certification. Quality control is of the utmost importance.
The company has developed on the basis of a philosophy of product
licence agreements with some of the best chemical-pharmaceutical
multinational laboratories such as Sanofi-Aventis, GlaxoSmithKline
and Lilly.
In addition, research by FAES (the Spanish group that owns Laboratórios
Vitória) has produced some very successful molecules, such as Hidrosmine,
a “phlebotonic” that is very well known by medics. This entrepreneurial
philosophy, together with an irreproachable ethical and deontological
posture in the Portuguese pharmaceutical market, allowed Laboratórios
Vitória to achieve its current dimensions and to look forward to
sustainable growth.
With a package of products that includes anti-ulceratives, non steroidal
anti-inflammatory drugs (NSAIDs), antibiotics, phlebotonics, platelet
aggregation inhibitors (PTls), expectorants, mineral supplements,
neuroleptics and anti-depressants, Laboratórios Vitória has achieved an
image of competence and quality amongst Portuguese medics.
This is no doubt the reason why the laboratory now occupies its
present position.

Luso Medicamenta
Lusomedicamenta S.A. is a pharmaceutical contract manufacturing
company operating in Portugal that specializes in the production of
solids, liquids and semi-solids.
We export about 58% of our production to 47 markets worldwide, and
we serve our clients, leading international pharmaceutical groups, with
the fullest range of and highest quality manufacturing solutions and
services. Facility design, together with fast changeover equipment, and
state-of-the-art information systems, optimises product and people
flow, providing very high flexible operations and reduced cycle times.
A dedicated and highly skilled technical team, and extensive
partnerships with national and international research and
development centres, provides our costumers with product development,
such as pre-formulation, formulation and analytical development, stability
studies, pilot batch production, and regulatory and technical support,
assuring full compliance during product life cycle.

Medinfar
Medinfar is an independent and fully integrated Portuguese pharmaceutical
group with R&D, production, marketing, sales and distribution.
Besides its own products Medinfar markets licensed products in partnerships
with international pharmaceutical companies. The company
manufactures and markets prescription medicines in the following
areas: General Practice, Cardiology, Gastroenterology and Dermatology.
It also has activities in non-prescription products, clinical and
hospital equipment. Always maintaining its commitment to quality,
its well-trained workforce and state of the art manufacturing facilities
aim to bring products of the highest quality to worldwide markets.
Medinfar increased its productive capacity in 2001, with the acquisition
of an industrial unit, Farmalabor, in Condeixa. This unit has an area of
47,000 m2 of which 6,000 m2 are a covered area, this being the main
industrial unit of Medinfar Group. The design and construction of
Farmalabor facilities and equipments follow not only European Union
Good Manufacturing Practice (GMP) but also the cGMP UE. Farmalabor
is licensed to produce solid, semi-solid and liquid pharmaceuticals and
also cosmetics and body hygiene products. Our relationship with the
most important international companies, combined with a detailed
knowledge of the Portuguese market and a Guaranteed Quality product
system, has made Medinfar an important international partner, in
both Portugal and and new markets. Medinfar products can be found
in more than 20 countries all over the world.

OM Portuguesa
OM Portuguesa was created to distribute the products of OM Pharma,
a Swiss pharmaceuticals manufacturer involved in the research,
development, production and distribution of synthetic pharmaceutical
specialities and biotechnological products.
Since it was set up in Portugal in 1954, OM has consolidated its presence
in the country and built a medicines factory in 1965.
Sustained growth consolidated its position in the national market.
It launched new products, most of which were produced in Portugal.
At the beginning of the 1970s, the distribution company began to
produce some of OM Pharma’s products and develop its own products.
In the mid-1990s, the group discussed making significant investment
in Portugal and decided to build a new production unit in Alfragide.
This was a large investment considering the size of the group and the
volume of business generated in Portugal.
However, this move by OM, in addition to seeking to manufacture
medicines of the highest quality for the national market and keep pace
with developments in the pharmaceutical industry, was built to deal
with production relocated from other units of the group to Portugal.
In order to respond to increased demands and responsibilities, the
company strengthened its workforce by recruiting highly qualified and
specialised technical staff. It also began the process of Quality Certification
and obtained ISO 9001 certification in 2000. The output of this industrial
unit supplies the national market and international markets in Europe,
Africa and South America.

Tecnifar
Tecnifar is a family company, founded in 1969, and with 100%
Portuguese capital. Tecnifar is built on foundations of diligence,
dedication, training, flexibility, determination and courage. Tecnifar
markets its own non-patented products and products under licence
from research companies, for example, MSD, AstraZeneca, Roche,
Pharmacia, J. Uriach, Angelini, Sigma-Tau, UCB and HRA Pharma. The
Tecnifar Group’s portfolio is essentially made up of ethical medicines
in the therapeutic areas of neuropsychiatry, cardiology, gynaecology,
pneumology, dermatology, orthopaedics and others. Tecnifar is proud
to belong to the group of Portuguese companies that works with major
and credible international companies in close cooperation with medics
to contribute to a permanently evolving medicinal products market. Its
ethical but aggressive position in the market has allowed it to gradually
increase its income and the number of partnerships with recognised
research and development companies.

Vida
The group exports 50% of its products. Its main markets are USA, EU
and Japan.
The Atral Cipan group also specialises in the transfer of technology
for the production of antibiotics using fermentation and chemical
synthesis. The group has implemented many projects in various
countries, including Finland, Brazil, Spain and India.
The group, which has 530 employees, invests 10% of its € 50 million
annual turnover in research and development of new APIs and new
finished dosage forms.

Contacts | Site map